8-K: Chain Bridge I Faces Nasdaq Delisting, Secures Extension for Business Combination

Chain Bridge I will be delisted from Nasdaq on November 19, 2024, but has secured a one-year extension to complete its business combination, with shares moving to the OTC market.

Summary

• Chain Bridge I will be delisted from the Nasdaq Capital Market on November 19, 2024, due to a failure to meet listing requirements.
• The company's Class A ordinary shares will then trade on the OTCQB Market under the symbol CBRRF, while warrants and units will trade on the Pink Open Market under CBRGF and CBGGF, respectively.
• There is no guarantee that a broker will continue to make a market in the company's securities on the OTC market.
• The company has extended the deadline to complete a business combination by one year, from November 15, 2024, to November 15, 2025.
• Shareholders approved the extension at an Extraordinary General Meeting on November 14, 2024.
• Holders of 550,947 Class A shares redeemed their shares for approximately $6,336,383 in cash.
• Fulton AC I LLC will contribute $4,557.36 per month to the trust account until the business combination is completed, the extended termination date is reached, or the company winds up.
• After redemptions, 3,014,736 Class A ordinary shares and 3,191,000 Class B ordinary shares are outstanding.

Sentiment

Score: 4

Explanation: The document contains both positive and negative elements. The extension and additional funding are positive, but the delisting from Nasdaq and the risk of liquidation are significant negatives. Overall, the sentiment is cautiously negative.

Positives

• The company has secured a one-year extension to complete its business combination, providing more time to find a suitable target.
• The company has secured additional funding from Fulton AC I LLC to support operations during the extension period.
• The company intends to relist on Nasdaq upon completion of the Phytanix Bio business combination.

Negatives

• The company's shares will be delisted from Nasdaq, which may reduce investor confidence and liquidity.
• There is no guarantee that a broker will continue to make a market in the company's securities on the OTC market.
• If the Phytanix Bio business combination is not consummated, the delisting will have a material adverse impact on the company's ability to locate another target and could lead to liquidation.

Risks

• The delisting from Nasdaq could negatively impact the company's ability to attract investors and complete a business combination.
• The company's securities may experience reduced liquidity and price volatility on the OTC market.
• Failure to complete the Phytanix Bio business combination or find another target could result in liquidation and the loss of shareholder value.
• There is a risk that the company may not be able to relist on Nasdaq even if the Phytanix Bio business combination is completed.

Future Outlook

The company will apply to list its securities on Nasdaq Capital Markets upon consummation of the Phytanix Bio Business Combination. If the business combination is not completed, the company may be forced to liquidate.

Management Comments

• We do not expect the delisting to impact our ability to consummate the previously disclosed business combination with Phtytanix Bio (the Phytanix Business Combination).
• Regardless of where our securities are traded, the surviving Company will apply to list its securities on Nasdaq Capital Markets upon consummation of the Phytanix Business Combination.

Industry Context

This announcement is typical for special purpose acquisition companies (SPACs) that are approaching their deadline to complete a business combination. The delisting and move to the OTC market is a common consequence of failing to meet Nasdaq's listing requirements. The extension and additional funding are attempts to avoid liquidation.

Comparison to Industry Standards

• Many SPACs face similar challenges with deadlines and delisting. For example, several SPACs have moved to the OTC market after failing to complete a business combination within the initial timeframe.
• The redemption rate of 550,947 shares is relatively high, indicating some shareholder concern about the company's prospects.
• The monthly contribution from Fulton AC is a common mechanism used by SPACs to extend their lifespan and maintain operations while seeking a target.
• The one-year extension is within the typical range for SPACs seeking additional time to complete a deal.

Corporate Governance

Stakeholder Impact

• Shareholders will experience a change in trading venue from Nasdaq to the OTC market.
• Shareholders who redeemed their shares received cash from the trust account.
• Shareholders who did not redeem their shares will continue to hold shares in the company, with the potential for future appreciation if a business combination is completed.
• Employees may be impacted by the uncertainty surrounding the company's future.

Next Steps

• The company will continue to pursue the Phytanix Bio business combination.
• The company will trade on the OTCQB and Pink Open Markets.
• The company will apply to relist on Nasdaq upon completion of the business combination.

Key Dates

Keywords

delisting, Nasdaq, OTCQB, OTC, business combination, extension, redemption, Phytanix Bio, liquidation, special purpose acquisition company, SPAC